|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5428156A
(en)
|
1993-04-02 |
1995-06-27 |
Associated Universities, Inc. |
Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
|
|
US5707624A
(en)
|
1994-06-03 |
1998-01-13 |
The Regents Of The University Of Michigan |
Treatment of Kaposi's sarcoma by inhibition of scatter factor
|
|
US6214344B1
(en)
|
1995-06-02 |
2001-04-10 |
Genetech, Inc. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
|
US5646036A
(en)
|
1995-06-02 |
1997-07-08 |
Genentech, Inc. |
Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
|
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
EP0922102B1
(en)
|
1996-07-03 |
2010-04-21 |
Genentech, Inc. |
Hepatocyte growth factor receptor agonists and uses thereof
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
CA2516236A1
(en)
|
2003-02-13 |
2004-08-26 |
Pharmacia Corporation |
Antibodies to c-met for the treatment of cancers
|
|
ITMI20031127A1
(it)
|
2003-06-05 |
2004-12-06 |
Uni Degli Studi Del Piemont E Orientale Am |
Anticorpi anti-hgf-r e loro uso
|
|
HRP20090324T1
(hr)
|
2003-06-06 |
2010-02-28 |
Genentech |
Moduliranje interakcije između hgf beta lanca i c-met
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CA2548282A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
|
SI1718677T1
(sl)
|
2003-12-19 |
2012-08-31 |
Genentech Inc |
Monovalentni protitelesni fragmenti, uporabni kot zdravila
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
AR048098A1
(es)
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
|
AU2005267720B2
(en)
|
2004-08-05 |
2012-02-23 |
Genentech, Inc. |
Humanized anti-cmet antagonists
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
US20070134243A1
(en)
*
|
2004-12-01 |
2007-06-14 |
Gazzard Lewis J |
Antibody drug conjugates and methods
|
|
KR20080000613A
(ko)
|
2005-03-25 |
2008-01-02 |
제넨테크, 인크. |
과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
CN101360511A
(zh)
|
2005-11-16 |
2009-02-04 |
法里巴·内耶里 |
用内源c-met配体和抑制剂抑制个体中的癌发生和/或转移的方法
|
|
US8388958B2
(en)
|
2006-02-06 |
2013-03-05 |
Metheresis Translational Research Sa |
Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
ATE517126T1
(de)
|
2006-03-20 |
2011-08-15 |
Seikagaku Kogyo Co Ltd |
Therapeutikum für rheumatoide arthritis
|
|
MX2008012485A
(es)
|
2006-03-30 |
2008-10-10 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos de c-met.
|
|
WO2007143168A2
(en)
|
2006-06-02 |
2007-12-13 |
Regeneron Pharmaceuticals, Inc. |
High affinity antibodies to human il-6 receptor
|
|
KR100829972B1
(ko)
|
2006-07-14 |
2008-05-16 |
재단법인서울대학교산학협력재단 |
항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
US8039598B2
(en)
|
2007-01-19 |
2011-10-18 |
Van Andel Research Institute |
Met fab and SCFV fragments
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
WO2008153744A2
(en)
|
2007-05-23 |
2008-12-18 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
|
US7892770B2
(en)
|
2007-08-24 |
2011-02-22 |
Van Andel Research Institute |
Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
|
|
US20110104166A1
(en)
|
2008-01-18 |
2011-05-05 |
Stankovic Konstantina M |
Methods and Compositions for Treating Polyps
|
|
KR20100135780A
(ko)
|
2008-03-06 |
2010-12-27 |
제넨테크, 인크. |
Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
|
|
WO2009111707A1
(en)
|
2008-03-06 |
2009-09-11 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
|
MX2010011808A
(es)
|
2008-04-30 |
2011-03-04 |
Immunogen Inc |
Conjugados potentes y enlazadores hidrofilicos.
|
|
AU2009246263B2
(en)
|
2008-05-14 |
2014-08-21 |
Amgen Inc. |
Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
|
|
WO2009142738A2
(en)
|
2008-05-21 |
2009-11-26 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
EP2127683A1
(en)
|
2008-05-29 |
2009-12-02 |
Metheresis Translational Research SA |
Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
|
|
US20090297439A1
(en)
|
2008-06-02 |
2009-12-03 |
Metheresis Translational Research Sa, |
Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
|
|
EP2143441A1
(en)
|
2008-07-08 |
2010-01-13 |
Pierre Fabre Medicament |
Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
|
|
KR101763559B1
(ko)
|
2008-07-21 |
2017-08-14 |
폴리테릭스 리미티드 |
생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
|
|
JP2012504606A
(ja)
|
2008-10-01 |
2012-02-23 |
ラディック インスティテュート フォー キャンサー リサーチ |
癌の治療方法
|
|
RU2011119638A
(ru)
|
2008-10-17 |
2012-11-27 |
Дженентек, Инк. |
Способ лечения
|
|
TW201019961A
(en)
|
2008-10-17 |
2010-06-01 |
Genentech Inc |
Combination therapy
|
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
MX2011010169A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-1/anti-c-met.
|
|
KR20110124369A
(ko)
|
2009-04-07 |
2011-11-16 |
로슈 글리카트 아게 |
이중특이적 항ｅｒｂｂ3／항ｃｍｅｔ 항체
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
CA2770617C
(en)
|
2009-08-10 |
2018-02-20 |
Mark Smith |
Reversible covalent linkage of functional molecules
|
|
EP2287197A1
(en)
|
2009-08-21 |
2011-02-23 |
Pierre Fabre Medicament |
Anti-cMET antibody and its use for the detection and the diagnosis of cancer
|
|
KR101671378B1
(ko)
|
2009-10-30 |
2016-11-01 |
삼성전자 주식회사 |
ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
|
|
KR101748707B1
(ko)
|
2009-11-27 |
2017-06-20 |
삼성전자주식회사 |
ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
|
|
BR112012022672B1
(pt)
*
|
2010-03-10 |
2020-04-14 |
Genmab As |
anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra
|
|
CN102933236B
(zh)
|
2010-04-15 |
2014-10-08 |
斯皮罗根有限公司 |
吡咯并苯二氮卓类及其结合物
|
|
AU2011252804A1
(en)
|
2010-05-14 |
2012-10-04 |
Genentech, Inc. |
Treatment methods
|
|
EP2808344A1
(en)
*
|
2010-06-01 |
2014-12-03 |
Monash University |
Antibodies directed to the receptor tyrosine kinase c-Met
|
|
EP2402370A1
(en)
|
2010-06-29 |
2012-01-04 |
Pierre Fabre Médicament |
Novel antibody for the diagnosis and/or prognosis of cancer
|
|
WO2012003338A1
(en)
|
2010-07-01 |
2012-01-05 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
WO2012005982A2
(en)
|
2010-07-06 |
2012-01-12 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Reporter for rna polymerase ii termination
|
|
WO2012030842A2
(en)
|
2010-09-03 |
2012-03-08 |
Academia Sinica |
Anti-c-met antibody and methods of use thereof
|
|
RU2013125457A
(ru)
|
2010-11-03 |
2014-12-10 |
Арджен-Икс Бв |
Комбинация антител против с-мет
|
|
PL2500036T3
(pl)
|
2011-03-18 |
2014-10-31 |
Metheresis Translational Res Sa |
Inhibitory met do zwiększania skuteczności radioterapii
|
|
WO2012136685A1
(en)
|
2011-04-04 |
2012-10-11 |
Pieris Ag |
Methods and compositions for anti-vegf and anti-c-met therapy
|
|
KR20120130658A
(ko)
|
2011-05-23 |
2012-12-03 |
주식회사 파멥신 |
펩타이드가 융합된 이중표적항체 및 그 용도
|
|
MX345538B
(es)
|
2011-05-27 |
2017-02-03 |
Ambrx Inc |
Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
|
|
KR101444837B1
(ko)
|
2011-06-03 |
2014-09-30 |
한국생명공학연구원 |
ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2013003680A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
|
MX2014002990A
(es)
|
2011-09-19 |
2014-05-21 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
|
|
WO2013043452A1
(en)
|
2011-09-20 |
2013-03-28 |
Eli Lilly And Company |
Anti-c-met antibodies
|
|
CA2850261C
(en)
*
|
2011-09-30 |
2021-04-20 |
Ablynx Nv |
C-met immunoglobulin single variable domains
|
|
KR20130037153A
(ko)
|
2011-10-05 |
2013-04-15 |
삼성전자주식회사 |
항 ｃ-Ｍｅｔ 항체 및 그의 용도
|
|
KR101865223B1
(ko)
|
2011-10-05 |
2018-06-08 |
삼성전자주식회사 |
항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
|
|
KR20130036993A
(ko)
|
2011-10-05 |
2013-04-15 |
삼성전자주식회사 |
ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
AU2012322933B2
(en)
|
2011-10-14 |
2017-02-02 |
Medimmune Limited |
Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
|
|
CN103998450B
(zh)
|
2011-10-14 |
2017-03-08 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓
|
|
CA2850375C
(en)
|
2011-10-14 |
2019-07-02 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
GB2504139B
(en)
*
|
2012-07-20 |
2014-12-31 |
Argen X Bv |
Antibodies to highly conserved targets produced by the immunisation of Camelidae species
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
KR101844479B1
(ko)
|
2011-11-17 |
2018-04-03 |
삼성전자주식회사 |
항 ｃ-Ｍｅｔ 항체 및 그의 용도
|
|
SG11201402485UA
(en)
|
2011-11-21 |
2014-06-27 |
Genentech Inc |
Purification of anti-c-met antibodies
|
|
KR101463098B1
(ko)
|
2011-11-28 |
2014-11-27 |
한국생명공학연구원 |
ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
|
|
IN2014CN04961A
(enExample)
|
2011-12-05 |
2015-09-18 |
Igenica Biotherapeutics Inc |
|
|
KR101910601B1
(ko)
|
2011-12-22 |
2018-10-23 |
삼성전자주식회사 |
면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
EP2870178B1
(en)
|
2012-05-09 |
2017-07-12 |
Eli Lilly and Company |
Anti-c-met antibodies
|
|
WO2013188752A2
(en)
|
2012-06-14 |
2013-12-19 |
The Schepens Eye Research Institute |
Treatment and prevention of retinal injury and scarring
|
|
US10377827B2
(en)
|
2012-06-21 |
2019-08-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
|
KR101938698B1
(ko)
|
2012-07-23 |
2019-01-16 |
삼성전자주식회사 |
Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
|
|
EP2708556B1
(en)
|
2012-09-12 |
2018-11-07 |
Samsung Electronics Co., Ltd |
Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
|
|
LT2911699T
(lt)
|
2012-10-23 |
2018-03-26 |
Synaffix B.V. |
Modifikuotas antikūnas, antikūnų konjugatas ir jų gavimo būdas
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
EA031184B1
(ru)
|
2012-11-21 |
2018-11-30 |
Янссен Байотек, Инк. |
БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
|
|
WO2014085821A2
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-met
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
TW201444872A
(zh)
|
2013-03-06 |
2014-12-01 |
Merrimack Pharmaceuticals Inc |
抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
|
|
US9062104B2
(en)
|
2013-03-14 |
2015-06-23 |
Alderbio Holdings Llc |
Therapeutic use of antibodies to HGF
|
|
US9481725B2
(en)
|
2013-03-14 |
2016-11-01 |
Alderbio Holdings, Llc |
Antibodies to HGF and compositions containing
|
|
US9732150B2
(en)
|
2013-03-14 |
2017-08-15 |
Alderbio Holdings Llc |
Therapeutic use of antibodies to HGF
|
|
EP2968593B1
(en)
*
|
2013-03-15 |
2024-11-20 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
KR102029137B1
(ko)
|
2013-03-27 |
2019-10-08 |
삼성전자주식회사 |
EGFR 길항제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
KR102049991B1
(ko)
|
2013-03-28 |
2019-12-02 |
삼성전자주식회사 |
항 c-Met/항 Her2 이중 특이 항체
|
|
US9535055B2
(en)
|
2013-03-28 |
2017-01-03 |
Samsung Electronics Co., Ltd. |
Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker
|
|
KR102042174B1
(ko)
|
2013-03-29 |
2019-11-08 |
삼성전자주식회사 |
인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
|
|
KR102074421B1
(ko)
|
2013-03-29 |
2020-02-10 |
삼성전자주식회사 |
항 c-Met/항 EGFR 이중 특이 항체
|
|
EP2786764B1
(en)
|
2013-04-01 |
2017-03-08 |
Samsung Electronics Co., Ltd. |
Combination therapy using anti-c-met antibody and sorafenib
|
|
EP2786765B1
(en)
|
2013-04-01 |
2018-10-03 |
Samsung Electronics Co., Ltd. |
Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor
|
|
KR102277813B1
(ko)
|
2013-04-02 |
2021-07-16 |
삼성전자주식회사 |
항 c-Met 항체의 항-이디오타입 항체
|
|
US10214593B2
(en)
|
2013-04-02 |
2019-02-26 |
Samsung Electronics Co., Ltd. |
Anti-idiotype antibody against anti-c-MET antibody
|
|
KR102060540B1
(ko)
|
2013-04-03 |
2019-12-31 |
삼성전자주식회사 |
항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
|
|
JP6491642B2
(ja)
|
2013-04-30 |
2019-03-27 |
エージェンシー フォー サイエンス， テクノロジー アンド リサーチ |
ｍＡｂ２抗Ｍｅｔ抗体
|
|
KR101536668B1
(ko)
|
2013-06-18 |
2015-07-15 |
사회복지법인 삼성생명공익재단 |
인간 및 마우스 c-Met에 교차결합하는 항체 및 그의 용도
|
|
US9567641B2
(en)
|
2013-07-03 |
2017-02-14 |
Samsung Electronics Co., Ltd. |
Combination therapy for the treatment of cancer using an anti-C-met antibody
|
|
EP2824113B1
(en)
|
2013-07-09 |
2017-05-03 |
Samsung Electronics Co., Ltd |
Biomarker for selecting a subject for application of an anti-c-met antibody
|
|
KR102089591B1
(ko)
|
2013-07-29 |
2020-03-18 |
삼성전자주식회사 |
항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
|
|
MX373528B
(es)
|
2013-08-26 |
2020-04-21 |
Regeneron Pharma |
Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos.
|
|
US9717715B2
(en)
|
2013-11-15 |
2017-08-01 |
Samsung Electronics Co., Ltd. |
Method of combination therapy using an anti-C-Met antibody
|
|
KR102178323B1
(ko)
|
2013-11-29 |
2020-11-13 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
|
EP3077402B1
(en)
|
2013-12-02 |
2018-09-19 |
Hong Kong Baptist University |
Anticancer maytansinoids with two fused macrocyclic rings
|
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合ｅｇｆｒ及ｍｅｔ之多功能抗體
|
|
KR20150083689A
(ko)
|
2014-01-10 |
2015-07-20 |
삼성전자주식회사 |
항 c-Met 항체 정제 방법
|
|
KR102194142B1
(ko)
|
2014-01-20 |
2020-12-23 |
삼성전자주식회사 |
항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물
|
|
KR102127408B1
(ko)
|
2014-01-29 |
2020-06-29 |
삼성전자주식회사 |
항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
|
|
ES2824674T3
(es)
|
2014-03-19 |
2021-05-13 |
Univ Zuerich |
Agentes quelantes bifuncionales multidentados para la complejación de radionúclidos en el diagnóstico y la terapia
|
|
EP2937421B1
(en)
|
2014-04-03 |
2018-10-24 |
Samsung Electronics Co., Ltd |
Biomarker for predicting effect of an anti-C-met antibody
|
|
US9975960B2
(en)
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
|
WO2015182796A1
(en)
|
2014-05-26 |
2015-12-03 |
Samsung Electronics Co., Ltd. |
Composition for combination therapy comprising anti-her2 antibody and anti-c-met antibody
|
|
KR101615619B1
(ko)
|
2014-08-07 |
2016-04-26 |
주식회사 파멥신 |
c-Met 특이적 인간 항체 및 그 제조방법
|
|
KR102259232B1
(ko)
|
2014-08-25 |
2021-05-31 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
|
WO2016042412A1
(en)
|
2014-09-16 |
2016-03-24 |
Symphogen A/S |
Anti-met antibodies and compositions
|
|
KR102390359B1
(ko)
|
2014-09-29 |
2022-04-22 |
삼성전자주식회사 |
폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
|
|
WO2016060297A1
(ko)
|
2014-10-16 |
2016-04-21 |
주식회사 파멥신 |
VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
|
|
US20180280531A1
(en)
|
2014-12-08 |
2018-10-04 |
Sorrento Therapeutics, Inc. |
C-met antibody drug conjugate
|
|
SG11201707148PA
(en)
*
|
2015-03-27 |
2017-10-30 |
Regeneron Pharma |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
CN106188293A
(zh)
|
2015-04-17 |
2016-12-07 |
江苏恒瑞医药股份有限公司 |
抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
|
|
CA3003759A1
(en)
|
2015-11-03 |
2017-05-11 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
|
WO2017087603A1
(en)
|
2015-11-18 |
2017-05-26 |
Sorrento Therapeutics, Inc. |
Chemically-locked bispecific antibodies
|
|
CN108779127B
(zh)
*
|
2016-01-25 |
2022-07-05 |
里珍纳龙药品有限公司 |
美登素类化合物衍生物、其偶联物和使用方法
|
|
US10927177B2
(en)
|
2016-02-05 |
2021-02-23 |
Helixmith Co., Ltd |
Methods of treatment using anti-c-met antibodies
|
|
RU2740996C2
(ru)
|
2016-05-17 |
2021-01-22 |
Эббви Байотерапьютикс Инк. |
КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
RS61932B1
(sr)
|
2016-09-14 |
2021-07-30 |
Merck Patent Gmbh |
Antitela na c-met i njihovi konjugati leka sa antitelom za efikasnu inhibiciju tumora
|
|
WO2018069851A2
(en)
|
2016-10-11 |
2018-04-19 |
Sorrento Therapeutics, Inc. |
C-met antibody drug conjugate
|
|
KR20190068550A
(ko)
|
2016-10-14 |
2019-06-18 |
쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 |
항-c met 항체-세포독성 약물 컨쥬게이트의 의학적 용도
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
HRP20210922T1
(hr)
|
2016-11-23 |
2021-09-03 |
Eli Lilly And Company |
Konjugati protutijela protiv met s lijekom
|
|
WO2018221969A1
(en)
|
2017-05-30 |
2018-12-06 |
Chong Kun Dang Pharmaceutical Corp. |
A novel anti-c-met antibody and use thereof
|
|
WO2018223958A1
(zh)
|
2017-06-06 |
2018-12-13 |
江苏恒瑞医药股份有限公司 |
一种含c-Met抗体药物偶联物的药物组合物及其用途
|
|
TWI726217B
(zh)
*
|
2017-06-15 |
2021-05-01 |
財團法人生物技術開發中心 |
含有抗globo h抗體之抗體－藥物共軛物及其用途
|
|
DK3665198T3
(da)
|
2017-08-09 |
2025-04-28 |
Merus Nv |
Antistoffer, der binder egfr og cmet
|
|
KR20190038173A
(ko)
|
2017-09-29 |
2019-04-08 |
서울대학교산학협력단 |
항 c-Met 항체 및 이의 용도
|
|
KR20190038174A
(ko)
|
2017-09-29 |
2019-04-08 |
서울대학교산학협력단 |
항 c-Met 항체 및 이의 용도
|
|
CN113727757A
(zh)
*
|
2019-02-21 |
2021-11-30 |
瑞泽恩制药公司 |
使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法
|
|
MX2022002886A
(es)
|
2019-09-16 |
2022-04-06 |
Regeneron Pharma |
Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
|
|
WO2022171115A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
微境生物医药科技(上海)有限公司 |
用于adc制备的喜树碱衍生物
|